Non-mucinous epithelial ovarian cancer
Conditions
Interventions
Phase I:N/A
Phase II:N/A
Sponsors
The First Affiliated Hospital of University of Science and Technology of China
Eligibility
Sex/Gender
Female
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: ? Women aged 18-90; ? After initial treatment in our hospital, non-mucinous epithelial ovarian cancer (including serous, endometrioid, clear cell carcinoma and mixed carcinoma) was confirmed by at least 2 or more physicians at the level of associate chief physicians in the department of pathology; ? Patients in the retrospective cohort were diagnosed between January 1, 2018 and December 31, 2020, and those in the validation cohort were diagnosed between January 1, 2021 and December 31, 2022; ? The level of serum CEA was normal; ? Treatment options included standard ovarian cancer staging or primary or intermediate tumor cell reduction; ? The patient's medical record information is complete, the follow-up results are complete, and the pathological report is accurate and reliable (including: Age, BMI, menopausal status, complications, primary site, tumor size, water, or intraoperative radiographic findings, lymph node metastasis and sizes before and after treatment, tumor markers, blood routine, biochemical and follow-up treatment, postoperative residual lesion size, postoperative pathology, installment, operation complexity rating, disseminated score, plan and course of chemotherapy, relapse time, Time of death etc.).
Exclusion criteria
Exclusion criteria: ? Other pathological types of ovarian malignancy (mixed ovarian tumor with mucinous exclusion); ? Have other malignant tumors or multiple primary tumors at the same time (excluding breast cancer within 2 years); ? With HIV, hepatitis B and other active infectious diseases; ? Other disease factors influencing ca19-9 values (acute pancreatitis, cholecystitis, cholestatic cholangitis, cirrhosis, hepatitis and other diseases); ? Patients who have participated in other biomedical studies or received experimental treatment in the past 30 days, unless approved by the investigator; ? The subjects are not willing to participate in the study; ? The researcher thinks that the subjects are not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactZhou Ying
The First Affiliated Hospital of University of Science and Technology of China
Outcome results
None listed